Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Cisplatin is a potent chemotherapeutic agent, however, its nephrotoxicity manifested by acute
kidney injury (AKI) often limits applicability. Dipeptidylpeptidase-4 (DPP4) inhibitors are
well known to improve glucose intolerance by augmentation of endogenous glucagon like peptide
(GLP-1) and glucose-dependent insulinotropic peptide (GIP). DPP4 inhibitor also has the
potential anti-apoptotic and renoprotective effect in a mouse model of cisplatin-induced AKI.
This is a single-center, randomized, double-blind, parallel-group, placebo-controlled,
prospective study to investigate the renoprotective effect of DPP4 inhibitor on
cisplatin-induced AKI. A total 182 patients, who are scheduled to treat with cisplatin, will
be recruited and randomly assigned to either Gemigliptin or placebo groups. Subjects will
take study drugs for 8 days starting from one day before cisplatin treatment. Serum
creatinine (Cr) and estimated glomerular filtration rate (eGFR) will be measured at 7 days
after cisplatin treatment.